Trials / Completed
CompletedNCT06228846
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
An Open-Label Phase I Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of YY001 in Patients with Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D) were observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YY001 | Oral |
Timeline
- Start date
- 2022-07-14
- Primary completion
- 2024-04-30
- Completion
- 2024-05-30
- First posted
- 2024-01-29
- Last updated
- 2025-01-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06228846. Inclusion in this directory is not an endorsement.